Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Status:
Recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of
Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure
reduced ejection fraction ( HFrEF) with and without diabetes mellitus and is to evaluate
short-term effect of these drugs using the cardiac biomarkers Neopterin.